Abstract
Postmenopausal women make up one of the fastest growing populations in the United States. Women typically have a higher incidence of cardiovascular disease following menopause. One of the major risk factors for cardiovascular disease is hypertension, and after menopause, blood pressure (BP) increases progressively in women. Also after menopause, the progression of renal disease increases in women compared with aged matched men. However, the mechanism( s) responsible for the post-menopausal increase in BP and renal injury are yet to be elucidated. Moreover the best therapeutic options to treat postmenopausal hypertension in women are not clear. Hypertension in postmenopausal women are usually associated with other cardiovascular risk factors, such as dyslipidemias, visceral obesity and endothelial dysfunction. Recently it became apparent that in a large number of hypertensive postmenopausal women, their BP is not well controlled with conventional antihypertensive medications. A clear understanding of the complex pathogenesis of postmenopausal hypertension is needed in order to offer the best therapeutic options for these women.
Keywords: dyslipidemias, cardiovascular risk factors, renal disease, hypertension, cardiovascular disease, visceral obesity, sex steroids sympathetic, menopause, endothelin, blood pressure, angiotensin II, Aldosterone
Current Topics in Medicinal Chemistry
Title: A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Volume: 11 Issue: 13
Author(s): Jane F. Reckelhoff, Radu Iliescu, Damian G. Romero and Licy L. Yanes
Affiliation:
Keywords: dyslipidemias, cardiovascular risk factors, renal disease, hypertension, cardiovascular disease, visceral obesity, sex steroids sympathetic, menopause, endothelin, blood pressure, angiotensin II, Aldosterone
Abstract: Postmenopausal women make up one of the fastest growing populations in the United States. Women typically have a higher incidence of cardiovascular disease following menopause. One of the major risk factors for cardiovascular disease is hypertension, and after menopause, blood pressure (BP) increases progressively in women. Also after menopause, the progression of renal disease increases in women compared with aged matched men. However, the mechanism( s) responsible for the post-menopausal increase in BP and renal injury are yet to be elucidated. Moreover the best therapeutic options to treat postmenopausal hypertension in women are not clear. Hypertension in postmenopausal women are usually associated with other cardiovascular risk factors, such as dyslipidemias, visceral obesity and endothelial dysfunction. Recently it became apparent that in a large number of hypertensive postmenopausal women, their BP is not well controlled with conventional antihypertensive medications. A clear understanding of the complex pathogenesis of postmenopausal hypertension is needed in order to offer the best therapeutic options for these women.
Export Options
About this article
Cite this article as:
F. Reckelhoff Jane, Iliescu Radu, G. Romero Damian and L. Yanes Licy, A Single Pill to Treat Postmenopausal Hypertension? Not Yet, Current Topics in Medicinal Chemistry 2011; 11 (13) . https://dx.doi.org/10.2174/156802611796117667
DOI https://dx.doi.org/10.2174/156802611796117667 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Iron Overload is Associated with Perihematoma Edema Growth Following Intracerebral Hemorrhage that may Contribute to In-hospital Mortality and Long-term Functional Outcome
Current Neurovascular Research Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Factors which Influence the Levels of ST-2, Galectin-3 and MMP-9 in Acute Coronary Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment
Current Medicinal Chemistry The Frequency and Risk Factors of Diabetic Foot Ulcer Recurrence Among Jordanian Patients with Diabetes
Current Diabetes Reviews The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Hyperuricemia and Hypertension — A Causal Relationship Ignored For All Too Long
Current Hypertension Reviews Pleiotropic Effects of ARB in Diabetes Mellitus
Current Vascular Pharmacology Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Cu-Based Solid Catalysts: Applications in Organic Transformations for NHeterocyclic Compounds
Current Organic Chemistry Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Letters in Drug Design & Discovery Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews